EGFR+ Lung Cancer

>

Latest News

FDA Considers Subcutaneous Amivantamab in EGFR-Mutated NSCLC
FDA Considers Subcutaneous Amivantamab in EGFR-Mutated NSCLC

June 17th 2024

A biologics license application for subcutaneous amivantamab combined with recombinant human hyaluronidase has been submitted to the FDA for NSCLC indications.

Osimertinib Shows Potential to Alter SOC in Advanced EGFR+ NSCLC
Osimertinib Shows Potential to Alter SOC in Advanced EGFR+ NSCLC

June 2nd 2024

Treating Rare Driver Mutations in NSCLC: EGFR Exon 20 Insertions
Treating Rare Driver Mutations in NSCLC: EGFR Exon 20 Insertions

April 24th 2024

Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment

April 23rd 2024

FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC

April 9th 2024

Video Series
Video Interviews
Podcasts

More News